It is demonstrated that GM-CSF treatment of breast cancer slows tumor growth and metastasis by stimulating monocytes to express and release sVEGFR-1 which blocks detection of VEGF and inhibits angiogenesis both in vitro and in vivo35, 36. Here, CSF2 is linked to breast carcinoma.